MARKET COMPOSITE
SRGA - Surgalign Holdings Inc
Price
$0.00
+ 0.00 (0.00%)
Surgalign Holdings, Inc., a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It offers coflex interlaminar stabilization device, an implant for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; SImmetry sacroiliac joint fusion system, which decreases in opioid use, pain, and disability; and Fortilink IBF system with TETRAfuse ?3D technology. The company's implants are used in the fields of orthopedic, spine, sports medicine, plastic surgery, trauma, and other surgical procedures to repair and promote the natural healing of human bone and other human tissues; and to enhance surgical outcomes. It markets its products through its direct distribution force and various OEM relationships to healthcare providers, hospitals, and other healthcare facilities, as well as through a network of independent distributors. The company was founded in 1997 and is headquartered in Deerfield, Illinois.
Financials
Quarterly financials
(USD)Mar 2023Q/Q
Revenue16.7MM-19%
Gross Profit10.7MM-480%
Cost Of Revenue6.1MM-74%
Operating Income-1.1MM-98%
Operating Expenses24.4MM-46%
Net Income4.1MM-111%
R&D2.9MM-13%
G&A21.1MM-6%
Interest Expense252K-0%
Stock Chart
leak data

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Stock news

    Delisting to take effect on July 3, 2023; Company’s common stock is expected to begin trading on the OTC under the symbol SRGAQDEERFIELD, Ill., June 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on June 22, 2023, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”). Nasdaq has d

    DEERFIELD, Ill., June 20, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) (“Surgalign” or the “Company”) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced that the Company has entered into an asset purchase agreement (the “Asset Purchase Agreement”) to sell substantially all of its U.S. hardware and biomaterials assets and the equity interests in non-Debtor entities related to the Debtors’ h

    Company to showcase its upgraded HOLO Portal™ Surgical Guidance System and key products in its hardware spine and biologics portfolio DEERFIELD, Ill., May 23, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced today that it will be exhibiting at ISASS 2023 – the 23rd Annual Conference – sponsored by the International Society for Spine Surgery (“ISASS”

    DEERFIELD, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, today announced financial results for its 2023 first quarter ended March 31, 2023. 2023 First Quarter and Subsequent Corporate Highlights: Launch of HOLO™ AI Insights for Spine Imaging; collaboration with Dr. Alexander Vaccaro, Dr. Pierce Nunley and Spine Institute of Louisiana, and le

    New HOLO AI Insights application aims to advance research of neuroanatomy utilizing artificial intelligenceDEERFIELD, Ill., May 08, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, is proud to announce today, the release of HOLO™ AI Insights for use in neurovascular research. HOLO AI Insights, initially launched in March 2023 for spine imaging, enables custom

    DEERFIELD, Ill., May 04, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, today announced its plans to release financial results for its first quarter 2023 after the close of trading on May 11, 2023. Surgalign will host a conference call and audio webcast at 4:30 p.m. ET the same day. The conference call can be accessed by dialing (888) 437-3179 (U.S.) or 862

    DEERFIELD, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, is pleased to announce new collaborative alliances with Dr. Pierce Nunley and the Spine Institute of Louisiana, a prestigious medical facility and one of the top 20 patient-rated U.S. hospitals for best overall care, and Dr. Alexander Vaccaro, an advisor to Surgalign and one of the top-

    Surgalign President and CEO Terry Rich joins Proactive's Natalie Stoberman to discuss the company's focus on artificial intelligence and treating spinal injuries and degenerative conditions.

    DEERFIELD, Ill., April 13, 2023 (GLOBE NEWSWIRE) -- Surgalign Holdings, Inc., (NASDAQ: SRGA) a global medical technology company focused on elevating the standard of care by driving the evolution of digital surgery, announced today that on April 10, 2023, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the $10 million minimum stockholders’ equity requirement for co

    Surgalign Holdings ( NASDAQ:SRGA ) Full Year 2022 Results Key Financial Results Revenue: US$82.0m (down 9.4% from FY...